Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirbanibulin Ointment 1% for Superficial Basal Cell Carcinoma
NCT05713760Phase 2Completed
- Sponsor
- Austin Institute for Clinical Research
- Start
- Apr 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tirbanibulin in basal cell carcinoma (BCC), sponsored by Austin Institute for Clinical Research. Primary endpoint: Complete clearance rate of sBCC lesion at 51 days. Started Apr 2023; status: completed.
02
Drugs
tirbanibulin
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT05713760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05713760.